Evidence review

Sermorelin research

Sermorelin has real historical human evidence, strongest in pediatric growth-hormone deficiency. Adult studies are smaller and emphasize surrogate endocrine outcomes.

Pediatric evidence

Multicenter research evaluated GHRH(1-29) in children with growth-hormone deficiency.

Adult limitations

Older-adult studies were small and focused on endocrine and metabolic markers.

Product boundary

Current research-vendor vials are not established as the historical regulated formulation.

Where evidence is strongest

The most substantial human record concerns pediatric growth-hormone deficiency and a defined prescription-drug context. Those studies do not establish broad adult anti-aging outcomes.

How to read current claims

Separate pediatric growth evidence from adult surrogate-marker studies.
Separate historical regulated product evidence from current compounded or research products.
Do not treat increased IGF-1 as proof of broad clinical benefit.